» Articles » PMID: 22930624

Parotid Carcinoma: Current Diagnostic Workup and Treatment

Overview
Specialty Oncology
Date 2012 Aug 30
PMID 22930624
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In this review we present recent progress in diagnostic workup, prognostic evaluation, treatment options and resulting outcomes. Whenever possible, complete resection remains the mainstay of treatment. Sacrifice of facial nerve branches is reserved for the clinically or electromyographically dysfunctioning facial nerve. Clinical or radiological neck disease demands combined surgery and radiotherapy. Treatment of the N0 neck is indicated for advanced stage-high grade tumors but the question remains unanswered whether this should be surgical or radiotherapeutic elective treatment. Surgery alone will cure low stage, low grade tumors, that show no additional negative prognostic factors following adequate resection. In all other tumors postoperative radiotherapy will improve locoregional control. This approach results in good locoregional control, in a way that distant metastasis remains the typical presentation of treatment failure. In this setting, the results of systemic treatment today remain limited, but a huge effort in the molecular biology field has been done to introduce targeted therapy into this domain of head and neck cancer. Disease control remains variable within the patient population. This variation can increasingly be predicted by systems that incorporate the combined information of multivariately identified and quantified prognostic factors into an individualized prognosis for the parotid carcinoma patient.

Citing Articles

Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability.

Peeperkorn S, Meulemans J, van Lierde C, Laenen A, Valstar M, Balm A Front Oncol. 2020; 10:1535.

PMID: 32984008 PMC: 7477337. DOI: 10.3389/fonc.2020.01535.


Reconstruction of complex defects of the extracranial facial nerve: technique of "the trifurcation approach".

Beutner D, Grosheva M Eur Arch Otorhinolaryngol. 2019; 276(6):1793-1798.

PMID: 30949826 DOI: 10.1007/s00405-019-05418-4.


Contemporary Management of Benign and Malignant Parotid Tumors.

Thielker J, Grosheva M, Ihrler S, Wittig A, Guntinas-Lichius O Front Surg. 2018; 5:39.

PMID: 29868604 PMC: 5958460. DOI: 10.3389/fsurg.2018.00039.

References
1.
Eapen L, Gerig L, Catton G, Danjoux C, Girard A . Impact of local radiation in the management of salivary gland carcinomas. Head Neck Surg. 1988; 10(4):239-45. DOI: 10.1002/j.1930-2398.1988.tb00006.x. View

2.
Cho K, Lee S, Lee Y . Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck. 1999; 21(5):414-9. DOI: 10.1002/(sici)1097-0347(199908)21:5<414::aid-hed6>3.0.co;2-m. View

3.
Eisele D, Sherman M, Koch W, Richtsmeier W, Wu A, Erozan Y . Utility of immediate on-site cytopathological procurement and evaluation in fine needle aspiration biopsy of head and neck masses. Laryngoscope. 1992; 102(12 Pt 1):1328-30. DOI: 10.1288/00005537-199212000-00002. View

4.
Bajaj Y, Singh S, Cozens N, Sharp J . Critical clinical appraisal of the role of ultrasound guided fine needle aspiration cytology in the management of parotid tumours. J Laryngol Otol. 2005; 119(4):289-92. DOI: 10.1258/0022215054020421. View

5.
Verdorfer I, Fehr A, Bullerdiek J, Scholz N, Brunner A, Krugmann J . Chromosomal imbalances, 11q21 rearrangement and MECT1-MAML2 fusion transcript in mucoepidermoid carcinomas of the salivary gland. Oncol Rep. 2009; 22(2):305-11. View